Johnson & Johnson said worldwide sales in 2024 increased 4.3% to $88.8 billion. U.S. sales were $50.3 billion, an increase of 8.3%, and international sales were $38.5 billion, a decrease of 0.5%.

1. 01

   Johnson & Johnson said worldwide sales in 2024 increased 4.3% to $88.8 billion. U.S. sales were $50.3 billion, an increase of 8.3%, and international sales were $38.5 billion, a decrease of 0.5%.

2. 02

   The company said Innovative Medicine segment sales in 2024 increased 4.0% to $57.0 billion. Oncology sales were $20.8 billion, an increase of 17.7%, and Immunology sales were $17.8 billion, a decrease of 1.2%.

3. 03

   Johnson & Johnson said MedTech segment sales in 2024 increased 4.8% to $31.9 billion. The Cardiovascular franchise, which includes Shockwave Medical acquired on May 31, 2024, achieved sales of $7.7 billion, an increase of 21.4%.

4. 04

   The company said cash flow from operations in 2024 was $24.3 billion and cash and cash equivalents at year-end were $24.1 billion. Total debt at year-end was $36.6 billion, up from $29.3 billion in the prior year.

Key figures

Fiscal year ended December 29, 2024

Revenue

$88.8B

Net income

$14.1B

EPS

$5.79

Gross profit

$61.4B

Operating cash flow

$24.3B

Analysis scope · Management's discussion (MD&A)We analyzed excerpts of the Management's Discussion and Analysis (MD&A) section (with omissions). Other sections of the report, such as the notes to the financial statements and risk factors, were not reviewed.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.